BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Br... (

BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer

Date:4/10/2008

- Strategic Collaboration with the National Cancer Institute's NABTT

Consortium -

BRISBANE, Calif., April 10 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme (GBM), the most common glioma in adults. BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in BiPar's DNA repair portfolio, crosses the blood-brain barrier, a unique property that enables its targeted investigation in the brain tumor setting. This study is being conducted by investigators from the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group. In addition to GBM, BiPar is currently enrolling BSI-201 in a randomized Phase 2 trial for triple-negative breast cancer and is initiating Phase 2 trials in uterine and BRCA-negative ovarian cancers.

"We believe a multi-drug strategy is the best approach to battling GBM. There is a significant need for new treatments that can offer GBM patients and their families additional hope," said Stuart A. Grossman, M.D., professor of oncology, medicine and neurological surgery at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital and the co-chairperson for this study.

"BSI-201 is a promising agent that has been well tolerated in combination with cytotoxic therapies in patients with solid tumors and potentially addresses a key pathway by which GBM cells resist the effects of existing medications. We are hopeful that BSI-201 will safely potentiate the power of current therapies for GBM and improve survival in this difficult-to-treat cancer," said Jaishri Blakeley, M.D., Assistant Professor of Neurology, Oncology and Neurosurgery at Johns Hopkins and the study chairperson for this study.

"The scientific observations that BSI-201 crosses the blood-brain barrier and has a mechanistic basis to synergize with t
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2
Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma

Post Your Comments:

(Date:11/9/2009)...ROCKVILLE, Md., Nov. 9 OriGene Tec... Technology in Sweden has adopted its VERIFY Tagge...an Protein Atlas program. This program is funded b...set up to explore the human proteome systematicall...h quality mono-specific antibodies in a high throu...

(Date:11/9/2009)...ST. LOUIS, Nov. 9, 2009 ...E: PFE ) today announced that they have entered i...Chesterfield Village Research Center located in Ch... Monsanto will acquire the property from Pfizer fo...ll continue to have operations at Chesterfield Vil...

(Date:11/9/2009)...VIRGINIA BEACH, Va., Nov. 9 LifeNe... announces the launch of Vertigraft Cervical Bio-I..., Preservon® is a new, proprietary glycerol-b...io-implants to be stored in a fully hydrated state...to freeze or freeze-dry bio-implants, doing away w...

Breaking Medicine Technology:Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program 2 Monsanto to Purchase Chesterfield Village Research Center From Pfizer 2 Monsanto to Purchase Chesterfield Village Research Center From Pfizer 3 LifeNet Health Announces First Bio-Implant with New Preservation Technology 2 Gene Therapy Shows Promise for Parkinsons 59471 1 Gene Therapy Shows Promise for Parkinsons 59471 2 Gene Therapy Shows Promise for Parkinsons 59471 3 Experts Summarize State of the Science in Autism Disorders 59468 1 Experts Summarize State of the Science in Autism Disorders 59468 2 Experts Summarize State of the Science in Autism Disorders 59468 3 Experts Summarize State of the Science in Autism Disorders 59468 4 Jack LaLanne Celebrated as Fitness Icon at Star Studded Birthday Bash 59465 1 Jack LaLanne Celebrated as Fitness Icon at Star Studded Birthday Bash 59465 2

[0] Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program [0] Monsanto to Purchase Chesterfield Village Research Center From Pfizer [0] LifeNet Health Announces First Bio-Implant with New Preservation Technology

...antly Reduced Signs of Disease Activity as Measure..., 2007 -- Genentech, Inc.,(NYSE: DNA) and Biogen... data from a Phase II clinical study of Rituxan&re...g multiple sclerosis,(RRMS) were presented today a... held in Boston. Rituxan is a therapeutic antibody...

...tzerland, May 2, 2007 – Merck,Serono S.A. (v...,safinamide, a new agent in Phase III development ...ptoms, were presented by Professor,Fabrizio Stocch...,Meeting in Boston, Massachusetts, USA. These data... blind, placebo-controlled,international trial. ,...

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting

(Date:11/9/2009)... 9 Speaker Nancy Pelos...ions in the Affordable Health Care for America ...aid and reduce Medicare Part D costs for people li...Saturday by a vote of 220 to 215: ,, "Effectiv...ality of life for thousands of Americans living wi...

(Date:11/9/2009)...e, Nov. 9 At a time when the 250,0...easingly concerned about finding affordable health...ption for 2010. ,, The Today,s Options® Pr...tage plan provides a cost-effective and comprehens... Supplement plan. People with Medicare can choose...

(Date:11/9/2009)... 9 The American Academy... than 75,000 clinically practicing physician assis...uds the U.S. House of Representatives for passing ...he Affordable Health Care for America Act. ,, "...will ultimately lower the cost of health care and ...

(Date:11/9/2009)...Research Hospital and the University of Florida Pr... to provide proton therapy for St. Jude patients. ... clinical study to evaluate the use of proton ther...n 3 years old. , Under the clinical protocol, ...rapy at the UF Proton Therapy Institute in Jackson...

(Date:11/9/2009)...er 9, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), t...ay announced the availability of INTUNIV (guanfaci...the United States for the treatment of Attention-D...nd adolescents ages 6 to 17. INTUNIV, a once-dail... nonscheduled alpha-2A receptor agonist approved f...

Breaking Medicine News(10 mins):Health News:Pelosi Applauds Provisions in Health Bill to Improve Access to Care, Medications for People Living With HIV/AIDS 2 Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2 Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2 Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2 Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 2 Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 3 Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 4

[0] Pelosi Applauds Provisions in Health Bill to Improve Access to Care, Medications for People Living With HIV/AIDS [0] Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option [0] American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill [0] St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial [0] Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies

...ustralians face increasingly large-scale,health ri...onment, ranging from,increases in weather extremes...health., Twelve of Australias top health and medic...ustralians., Released today by Research Australia,...

...research tracks the spread of HIV from Africa to A...s) -- New research into the genetic history of HIV...in Haiti during the middle of the last century, pr... into how HIV evolves and moves from place to plac...

...N, Pa., Oct. 30 ViroPharma Incorporated,(Nasdaq: ...he third quarter,and nine-months ended September 3... Clinical:, -- Patient enrollment began in a Pha...stem cell transplant patients; study enrollment ex...

...es Fiscal Year EPS Outlook for One-time Tax Benefi...e Company (NYSE: PG ) announced net sales growth ... Every reportable segment delivered,mid-single dig... Fabric & Home Care, Baby & Family Care and Groomi...

...CETON, N.J., Oct. 30 Medarex, Inc.,(Nasdaq: MEDX... at the,JPMorgan Small/Mid Cap Conference in Bosto...Time. Medarex,s presentation will be webcast live ...arex.com . About Medarex Medarex is a biopharmac...

...JOSEPH, Mich., Oct. 30 GeneGo, Inc., the leading,...t Elan Pharmaceuticals,Inc. licensed its flagship ...l be available to all scientists in research. Meta... very pleased that Elan chose GeneGo and we have h...

Healthy planet, places and people at risk AIDS Stopped in Haiti Before U.S.ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth Medarex to Present at the JPMorgan Small/Mid Cap Conference Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo

Light Guide Cables - 2.0mm

3mm Universal Light Guide

Fiberoptic Light Guide with Fixed ACMI™ Light Source End

Fiberoptic Light Guide, clip-on

Medicine Products:

Light Guide Cables - 2.0mm 3mm Universal Light Guide Fiberoptic Light Guide with Fixed ACMI™ Light Source End Fiberoptic Light Guide, clip-on

BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Br...( - Strategic Collaboration with th...),Health